Results 1 to 10 of about 13,923 (166)
Zhongshan Daxue xuebao. Yixue kexue ban, 2020 神经胶质瘤是中枢神经系统中最常见的原发肿瘤，其中过半数是WHOIV级的胶质母细胞瘤，即使接受包括了手术、同步放化疗及辅助化疗的治疗，其中位生寸期仍只有14.2个月。免疫抑制是恶性胶质瘤的重要特征，逆转免疫抑制的免疫治疗仍然是近年来最有希望提高胶质瘤患者治疗效果的方式。本文综述了胶质瘤的免疫治疗进展，以及胶质瘤微环境中调节性T细胞（Treg）与糖皮质激素诱导的肿瘤坏死因子受体（GITR）的研究进展，希望为恶性胶质瘤的免疫治疗提供新的研究思路。
牟永告
doaj +2 more sources
Zhongshan Daxue xuebao. Yixue kexue ban, 1990 用戊二醛使野苋菜花粉变应原聚合,再用凝胶层析法将大分子聚合变应原析出。免疫学实验表明该聚合变应原免疫原性不变而变应原性减低。28例支气管哮喘的临床对照研究表明,聚合变应原免疫治疗起效快,疗效好,可能减低气道的非特异反应性,未发现全身副反应。
doaj +2 more sources
Clinical analysis of anti-N-methyl-D-aspartate receptor encephalitis patients with cerebellar ataxia [PDF]
, 2021 摘要： 目的:分析总结合并小脑共济失调的抗N-甲基-D-天冬氨酸受体（NMDAR）脑炎患者的临床特点。方法:回顾分析北京协和医院2011—2019年诊治的抗NMDAR脑炎患者中合并小脑共济失调患者的临床表现、实验室检查结果、治疗与预后。结果:347例抗NMDAR脑炎患者中共有15例（4.3%）合并小脑共济失调，其中1例患者合并卵巢畸胎瘤，男性7例，女性8例，中位年龄28岁，从脑炎发病到出现小脑症状平均病程30.8 d，极期改良Rankin量表（mRS）评分平均3.73分 ...
任海涛 +7 more
core +1 more source
Chinese expert consensus on immunotherapy for gynecological malignant tumors (2023 edition) [PDF]
, 2023 Immunotherapy, as the fourth largest anti-tumor treatment method, has made breakthrough progress in the field of cancer treatment. Checkpoint inhibitors have been widely used in the treatment of various malignant tumors, and a lot of clinical evidence ...
Society of Onco-Endocrinology of Chinese Anti-Cancer Association
core +1 more source
珠三角地区变应性鼻炎和/或支气管哮喘患者皮下特异性免疫治疗依从性的真实世界研究 [PDF]
, 2022 目的了解珠三角地区变应性鼻炎（AR）和/或支气管哮喘患者（BA）中止皮下变应原免疫治疗（SCIT）的原因，为提高患者SCIT的依从性提供参考依据。方法本研究是一项回顾性、多中心、大样本的真实世界研究，收集和分析2015年1月到2020年12月在珠三角地区6家三甲医院接受SCIT的AR和/或BA患者的临床资料，并对中止治疗患者的进行电话随访。结果纳入1 244例接受SCIT的患者，中止治疗427例（脱落率为34.3%）；儿童、已婚、过敏家族史阳性、总IgE （tIgE）>200 U ...
唐隽 +7 more
core +1 more source
Advances in immunotherapy of advanced non-small cell lung cancer with EGFR mutation [PDF]
, 2023 The incidence of epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC) in Asians is significantly higher than that in Westerners. For the past few years, immune checkpoint inhibitors (ICIs) that target the programmed cell
HUANG Huayan +4 more
core +1 more source
Evaluation of medication treatment for Alzheimer's disease on clinical evidence [PDF]
, 2014 Objective To formulate the best treatment plan for Alzheimer's disease patients by evaluating the therapeutic efficacy and side effect of various evidence-based programs.
Ling LIU +3 more
core +2 more sources
Important clinical research progress in lung cancer in 2022 [PDF]
, 2023 Lung cancer remains the malignant tumor with the highest morbidity and mortality in China, among which non-small cell lung cancer (NSCLC) accounts for more than 80%.
SU Chunxia, ZHOU Caicun
core +1 more source
Clinical implication of PD-L2 in the prognosis assessment of HNSCC immunotherapy [PDF]
, 2023 Background and purpose: Programmed death-1 (PD-1) monoclonal antibody therapy plays an increasingly important role in the treatment of head and neck squamous cell carcinoma (HNSCC).
HUANG He, JU Houyu, YANG Wenyi, YAN Ming, REN Guoxin, HU Jingzhou
core +1 more source
Zhongshan Daxue xuebao. Yixue kexue ban, 2023 自然杀伤（NK）细胞是T细胞后具有临床应用前景的另一类抗肿瘤免疫细胞。NK 细胞的活性主要受其表面受体和免疫微环境的调控，胶质瘤较强的免疫抑制性肿瘤微环境使NK细胞免疫治疗效率较低。本综述从胶质瘤-NK细胞交互作用角度讨论NK细胞在脑胶质瘤免疫治疗中作用的最新研究进展，总结靶向NK 细胞的化合物、单克隆抗体和细胞因子疗法，重点讨论了基因修饰的NK细胞在胶质瘤免疫治疗的现状及趋势，以及胶质瘤细胞的相关免疫逃逸分子机制，为基于NK细胞的免疫治疗神经胶质瘤提供理论依据和新的思路。
孙士隆, 陈保东
doaj